Trillium Therapeutics Inc (TRIL)

[NY1972]

TTI-621 P1 Exclusion Criteria:

Known central nervous system disease involvement.
Allogeneic transplant within 100 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement.
History of hemolytic anemia or bleeding diathesis


CC90002 P1 Exclusion Criteria:

Active central nervous system (CNS) leukemia or known CNS leukemia.
Immediately life-threatening, severe complications of leukemia.
Impaired cardiac function or clinically significant cardiac diseases.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Prior autologous hematopoietic stem cell transplant ≤ 3 months.
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.
Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).
Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.
Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.
Pregnant or nursing females.
Known HIV infection.
Known chronic hepatitis B or C (HBV/HCV) infection.
Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
History of concurrent second cancers requiring active, ongoing systemic treatment.
Subjects for whom potentially curative anticancer therapy is available.